217eP Immunotherapy beyond trials: Dostarlimab in advanced endometrial cancer: A Portuguese multicenter experience
Dostarlimab was available in Portugal for advanced or recurrent endometrial cancer post–platinum therapy via early access(EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under EAP in June 2024. Until now, no national real-world data have been reported.
Authors
- A.G. Zanga
- JMC Rodrigues
- M.Q. Pereira
- I.S. Soares de Pinho
- M.T. Crisóstomo
- I.C. Gomes Fernandes
- B.D.S. Castanheira
- A.R.D.S. Lopes
- M.C. Couto
- R.Q. Ferreira
- P. Antunes Meireles
- P. Simões
- I. Miguel
- F. Macedo
- P.J.T.D. Castro
- F. Vaz
Institutions
- Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
- Hospitais da Universidade de Coimbra (PT)
- Hospital de São João (PT)
- Unidade Local de Saúde de São José (PT)
- Hospital Prof. Dr. Fernando Fonseca (PT)
- IPO Porto (PT)
- Unidade Local de Saúde de Trás-os-Montes e Alto Douro (PT)
- Centro Hospitalar Lisboa Norte (PT)
- Centro De Medicina Veterinária Anjos De Assis (PT)
- Centro Hospitalar de Lisboa Ocidental (PT)
- Hospital de Santo António (PT)
- Hospital Beatriz Ângelo (PT)
- Hospital of St. Francis Xavier (PT)
- Hospital Santo António dos Capuchos (PT)
- Hospital Garcia de Orta (PT)
- Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101300
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00